We're thrilled to announce that SKOUT®: real-time AI for polyp detection, will soon be available to gastroenterologists throughout the United States. Learn more about the latest technology for enhanced adenoma detection here: https://t.co/7jyvg3tDHq @provationmed

Join us live on YouTube tomorrow at 10:30 a.m. ET for a discussion about Observing Ramadan With IBD in partnership with @southasianIBD and @ImproveCareNow. Watch live: https://t.co/bKAu1fMDDy

Iterative Health is excited to announce a partnership with @FLResearchInst to bring AI Recruitment (AIR) technology to Florida, to help democratize access to novel IBD therapeutics for all patients, regardless of where they receive care. @FLDigestive https://t.co/UJMF0Sz9Vd

We’re on the list! Excited to share that Iterative Health has been included in @BuiltIn's Best Midsize Places to Work List in Boston! #2023BuiltInBest https://t.co/gYs7S9kDHd

Iterative Scopes is now Iterative Health! With this re-branding, we reinforce our commitment to advancing precision medicine and continuing to raise the bar for both accuracy and consistency in physician decision-making. Visit our new website: https://t.co/Qq8SR0YTms

Iterative Scopes announces a new partnership with One GI® to bring AI-Recruitment to their clinical research, starting at @Gastro1Memphis. Through this collaboration, both organizations hope to better democratize access to novel IBD therapeutics. @OneGICEO https://t.co/CEint6dYXB

We’re thrilled to announce that our real-time, computer-aided, polyp detection device SKOUT™ has received 510(k) clearance from the FDA. Read our new release to learn more about our registration study. SKOUT is not yet for sale in the US. @provationmed https://t.co/9klfcNn83u

The registration study for our real-time computer-aided polyp detection device SKOUT™ is featured on the cover of @AGA_Gastro! Check out the September issue to read our registration study results. SKOUT is not yet for sale in the US. @provationmed https://t.co/C2z4aLMHaJ

@BuiltInSF recently interviewed our Chief Product Officer Brice Wu to learn what a culture of ownership means for his team. https://t.co/vJqdWhS8m5

Check out our new video to learn how Iterative Scopes aims to revolutionize gastroenterology by delivering precision medicine and quality care to IBD patients. #ibd

In a video with @MDMagazine, @AasmaShaukatMD discusses data from our DDW 2022 late-breaking abstract showing that SKOUT™ demonstrated statistical superiority at overall adenoma detection compared to routine colonoscopy. Not currently for sale in the US.

Laura Mantell (@lfmantell) joins Iterative Scopes as VP of Life Sciences. In support of the company’s goal to help optimize IBD clinical trials, she will steer all life sciences, biopharma, and biotech partnerships. #artificialintelligence https://t.co/pz6eeRH4xC

This morning, @Clin_Info_News published an article written by Iterative Scopes SVP of Clinical Strategy, Chris Fourment, MD (@c4ment) on the topic, “How AI and Computer Vision Can Solve Challenges in IBD Drug Development” https://t.co/h47d27I3l7 #gastroenterology

Iterative Scopes announced at #DDW2022 that its computer-aided device, SKOUT(™), demonstrates statistical superiority at overall adenoma detection compared to routine colonoscopy.  @AasmaShaukatMD

At @DDWMeeting 2022, Iterative Scopes presented data created in collaboration with @LillyPad demonstrating how AI can improve endoscopic-disease severity scoring in ulcerative colitis. #DDW2022

With the addition of CRSG and Precision, Iterative Scopes has the opportunity to work more closely with different types of clinical trial sites and providers and to gain sophisticated insights about their needs and pain points.

Iterative Scopes is excited to announce that it has entered an AI-driven data sharing agreement with Pfizer to advance IBD clinical trials.

Thank you @Nasdaq for highlighting Iterative Scopes and our recent fundraise in Times Square!

Iterative Scopes has entered a collaboration with Janssen Research & Development, LLC (@JanssenGlobal) to augment Janssen’s clinical trials for IBD with the deployment of cutting-edge artificial intelligence (AI) and computer vision tools.

We are excited to announce that we have raised $150 million in Series B financing to advance AI-driven precision medicine for gastroenterology. This round was co-led by @insightpartners & @ClearlakeCap, and marks a total $182 million raised in 2021.